 | • レポートコード：MRC2Q12-17109 • 出版社/出版日：QYResearch / 2022年12月 • レポート形態：英文、PDF、108ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医療機器＆消耗品 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,450,400 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、セルフリー腫瘍DNA検出のグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。 セルフリー腫瘍DNA検出のアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 セルフリー腫瘍DNA検出の中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 セルフリー腫瘍DNA検出のヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生産面において、本レポートは2017年から2022年までのセルフリー腫瘍DNA検出の生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別のセルフリー腫瘍DNA検出の売上および2028年までの予測に焦点を当てています。 セルフリー腫瘍DNA検出のグローバル主要企業には、Biocept Inc.、Bio-Rad Laboratories Inc.、Fluxion Biosciences Inc.、F. Hoffmann-La Roche AG、Sysmex Europe SE、Qiagen、NeoGenomics Laboratories Inc.、Menarini Silicon Biosystems、Illumina Inc.、Guardant Health Inc.、Shanghai Biotecan Medical Diagnostics Co.,Ltd.などがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 セルフリー腫瘍DNA検出市場は、タイプとアプリケーションによって区分されます。世界のセルフリー腫瘍DNA検出市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。 【タイプ別セグメント】 液滴デジタルポリメラーゼ連鎖反応、タグ付きアンプリコンディープシーケンシング、その他 【アプリケーション別セグメント】 乳癌、胃癌、肝臓癌、その他 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - セルフリー腫瘍DNA検出製品概要 - タイプ別市場（液滴デジタルポリメラーゼ連鎖反応、タグ付きアンプリコンディープシーケンシング、その他） - アプリケーション別市場（乳癌、胃癌、肝臓癌、その他） - 調査の目的 ・エグゼクティブサマリー - 世界のセルフリー腫瘍DNA検出販売量予測2017-2028 - 世界のセルフリー腫瘍DNA検出売上予測2017-2028 - セルフリー腫瘍DNA検出の地域別販売量 - セルフリー腫瘍DNA検出の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別セルフリー腫瘍DNA検出販売量 - 主要メーカー別セルフリー腫瘍DNA検出売上 - 主要メーカー別セルフリー腫瘍DNA検出価格 - 競争状況の分析 - 企業M&A動向 ・タイプ別市場規模（液滴デジタルポリメラーゼ連鎖反応、タグ付きアンプリコンディープシーケンシング、その他） - セルフリー腫瘍DNA検出のタイプ別販売量 - セルフリー腫瘍DNA検出のタイプ別売上 - セルフリー腫瘍DNA検出のタイプ別価格 ・アプリケーション別市場規模（乳癌、胃癌、肝臓癌、その他） - セルフリー腫瘍DNA検出のアプリケーション別販売量 - セルフリー腫瘍DNA検出のアプリケーション別売上 - セルフリー腫瘍DNA検出のアプリケーション別価格 ・北米市場 - 北米のセルフリー腫瘍DNA検出市場規模（タイプ別、アプリケーション別） - 主要国別のセルフリー腫瘍DNA検出市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパのセルフリー腫瘍DNA検出市場規模（タイプ別、アプリケーション別） - 主要国別のセルフリー腫瘍DNA検出市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋のセルフリー腫瘍DNA検出市場規模（タイプ別、アプリケーション別） - 主要国別のセルフリー腫瘍DNA検出市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米のセルフリー腫瘍DNA検出市場規模（タイプ別、アプリケーション別） - 主要国別のセルフリー腫瘍DNA検出市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカのセルフリー腫瘍DNA検出市場規模（タイプ別、アプリケーション別） - 主要国別のセルフリー腫瘍DNA検出市場規模（トルコ、サウジアラビア） ・企業情報 Biocept Inc.、Bio-Rad Laboratories Inc.、Fluxion Biosciences Inc.、F. Hoffmann-La Roche AG、Sysmex Europe SE、Qiagen、NeoGenomics Laboratories Inc.、Menarini Silicon Biosystems、Illumina Inc.、Guardant Health Inc.、Shanghai Biotecan Medical Diagnostics Co.,Ltd. ・産業チェーン及び販売チャネル分析 - セルフリー腫瘍DNA検出の産業チェーン分析 - セルフリー腫瘍DNA検出の原材料 - セルフリー腫瘍DNA検出の生産プロセス - セルフリー腫瘍DNA検出の販売及びマーケティング - セルフリー腫瘍DNA検出の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - セルフリー腫瘍DNA検出の産業動向 - セルフリー腫瘍DNA検出のマーケットドライバー - セルフリー腫瘍DNA検出の課題 - セルフリー腫瘍DNA検出の阻害要因 ・主な調査結果 |
Cell-free tumor DNA (circulating tumor DNA, ctDNA) testing, the so-called “liquid biopsy”. ctDNA refers to the DNA released by tumor cells into the blood circulatory system, which contains information on tumor-derived mutations and gene variations. ctDNA is a tumor marker with broad application prospects, high sensitivity and high specificity, and is suitable for a variety of tumors, providing an opportunity for non-invasive sampling of tumors.
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Cell-free Tumor DNA Detection estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Cell-free Tumor DNA Detection is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Cell-free Tumor DNA Detection is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Cell-free Tumor DNA Detection is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key companies of Cell-free Tumor DNA Detection include Biocept Inc., Bio-Rad Laboratories Inc., Fluxion Biosciences Inc., F. Hoffmann-La Roche AG, Sysmex Europe SE, Qiagen, NeoGenomics Laboratories Inc., Menarini Silicon Biosystems and Illumina Inc., etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, revenue and gross margin. Major players’ headquarters, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Cell-free Tumor DNA Detection companies, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Cell-free Tumor DNA Detection market. Further, it explains the major drivers and regional dynamics of the global Cell-free Tumor DNA Detection market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable revenue, market share and rank data of the companies for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
Biocept Inc.
Bio-Rad Laboratories Inc.
Fluxion Biosciences Inc.
F. Hoffmann-La Roche AG
Sysmex Europe SE
Qiagen
NeoGenomics Laboratories Inc.
Menarini Silicon Biosystems
Illumina Inc.
Guardant Health Inc.
Shanghai Biotecan Medical Diagnostics Co.,Ltd.
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides revenue forecast data by type and by application segments based on value for the period 2017-2028.
Cell-free Tumor DNA Detection Segment by Type
Droplet Digital Polymerase Chain Reaction
Tagged-Amplicon Deep Sequencing
Others
Cell-free Tumor DNA Detection Segment by Application
Breast Cancer
Stomach Cancer
Liver Cancer
Other
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Cell-free Tumor DNA Detection market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Cell-free Tumor DNA Detection market size. Analyses of the global market trends, with historic market revenue data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Cell-free Tumor DNA Detection, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Cell-free Tumor DNA Detection, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Cell-free Tumor DNA Detection revenue, market share and industry ranking of main companies, data from 2017 to 2022. Identification of the major stakeholders in the global Cell-free Tumor DNA Detection market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2017 to 2028. Evaluation and forecast the market size for Cell-free Tumor DNA Detection revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Biocept Inc., Bio-Rad Laboratories Inc., Fluxion Biosciences Inc., F. Hoffmann-La Roche AG, Sysmex Europe SE, Qiagen, NeoGenomics Laboratories Inc., Menarini Silicon Biosystems and Illumina Inc., etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Cell-free Tumor DNA Detection in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Cell-free Tumor DNA Detection companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: Asia Pacific by type, by application and by country/region, revenue for each segment.
Chapter 9: Latin America by type, by application and by country, revenue for each segment.
Chapter 10: Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Cell-free Tumor DNA Detection revenue, gross margin, and recent development, etc.
Chapter 12: Analyst’s Viewpoints/Conclusions
1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Cell-free Tumor DNA Detection Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Droplet Digital Polymerase Chain Reaction
1.2.3 Tagged-Amplicon Deep Sequencing
1.2.4 Others
1.3 Market by Application
1.3.1 Global Cell-free Tumor DNA Detection Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Breast Cancer
1.3.3 Stomach Cancer
1.3.4 Liver Cancer
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Cell-free Tumor DNA Detection Market Perspective (2017-2028)
2.2 Cell-free Tumor DNA Detection Growth Trends by Region
2.2.1 Cell-free Tumor DNA Detection Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Cell-free Tumor DNA Detection Historic Market Size by Region (2017-2022)
2.2.3 Cell-free Tumor DNA Detection Forecasted Market Size by Region (2023-2028)
2.3 Cell-free Tumor DNA Detection Market Dynamics
2.3.1 Cell-free Tumor DNA Detection Industry Trends
2.3.2 Cell-free Tumor DNA Detection Market Drivers
2.3.3 Cell-free Tumor DNA Detection Market Challenges
2.3.4 Cell-free Tumor DNA Detection Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Cell-free Tumor DNA Detection Players by Revenue
3.1.1 Global Top Cell-free Tumor DNA Detection Players by Revenue (2017-2022)
3.1.2 Global Cell-free Tumor DNA Detection Revenue Market Share by Players (2017-2022)
3.2 Global Cell-free Tumor DNA Detection Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Cell-free Tumor DNA Detection Revenue
3.4 Global Cell-free Tumor DNA Detection Market Concentration Ratio
3.4.1 Global Cell-free Tumor DNA Detection Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Cell-free Tumor DNA Detection Revenue in 2021
3.5 Cell-free Tumor DNA Detection Key Players Head office and Area Served
3.6 Key Players Cell-free Tumor DNA Detection Product Solution and Service
3.7 Date of Enter into Cell-free Tumor DNA Detection Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Cell-free Tumor DNA Detection Breakdown Data by Type
4.1 Global Cell-free Tumor DNA Detection Historic Market Size by Type (2017-2022)
4.2 Global Cell-free Tumor DNA Detection Forecasted Market Size by Type (2023-2028)
5 Cell-free Tumor DNA Detection Breakdown Data by Application
5.1 Global Cell-free Tumor DNA Detection Historic Market Size by Application (2017-2022)
5.2 Global Cell-free Tumor DNA Detection Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Cell-free Tumor DNA Detection Market Size (2017-2028)
6.2 North America Cell-free Tumor DNA Detection Market Size by Type
6.2.1 North America Cell-free Tumor DNA Detection Market Size by Type (2017-2022)
6.2.2 North America Cell-free Tumor DNA Detection Market Size by Type (2023-2028)
6.2.3 North America Cell-free Tumor DNA Detection Market Share by Type (2017-2028)
6.3 North America Cell-free Tumor DNA Detection Market Size by Application
6.3.1 North America Cell-free Tumor DNA Detection Market Size by Application (2017-2022)
6.3.2 North America Cell-free Tumor DNA Detection Market Size by Application (2023-2028)
6.3.3 North America Cell-free Tumor DNA Detection Market Share by Application (2017-2028)
6.4 North America Cell-free Tumor DNA Detection Market Size by Country
6.4.1 North America Cell-free Tumor DNA Detection Market Size by Country (2017-2022)
6.4.2 North America Cell-free Tumor DNA Detection Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Cell-free Tumor DNA Detection Market Size (2017-2028)
7.2 Europe Cell-free Tumor DNA Detection Market Size by Type
7.2.1 Europe Cell-free Tumor DNA Detection Market Size by Type (2017-2022)
7.2.2 Europe Cell-free Tumor DNA Detection Market Size by Type (2023-2028)
7.2.3 Europe Cell-free Tumor DNA Detection Market Share by Type (2017-2028)
7.3 Europe Cell-free Tumor DNA Detection Market Size by Application
7.3.1 Europe Cell-free Tumor DNA Detection Market Size by Application (2017-2022)
7.3.2 Europe Cell-free Tumor DNA Detection Market Size by Application (2023-2028)
7.3.3 Europe Cell-free Tumor DNA Detection Market Share by Application (2017-2028)
7.4 Europe Cell-free Tumor DNA Detection Market Size by Country
7.4.1 Europe Cell-free Tumor DNA Detection Market Size by Country (2017-2022)
7.4.2 Europe Cell-free Tumor DNA Detection Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Cell-free Tumor DNA Detection Market Size (2017-2028)
8.2 Asia-Pacific Cell-free Tumor DNA Detection Market Size by Type
8.2.1 Asia-Pacific Cell-free Tumor DNA Detection Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Cell-free Tumor DNA Detection Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Cell-free Tumor DNA Detection Market Share by Type (2017-2028)
8.3 Asia-Pacific Cell-free Tumor DNA Detection Market Size by Application
8.3.1 Asia-Pacific Cell-free Tumor DNA Detection Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Cell-free Tumor DNA Detection Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Cell-free Tumor DNA Detection Market Share by Application (2017-2028)
8.4 Asia-Pacific Cell-free Tumor DNA Detection Market Size by Region
8.4.1 Asia-Pacific Cell-free Tumor DNA Detection Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Cell-free Tumor DNA Detection Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Cell-free Tumor DNA Detection Market Size (2017-2028)
9.2 Latin America Cell-free Tumor DNA Detection Market Size by Type
9.2.1 Latin America Cell-free Tumor DNA Detection Market Size by Type (2017-2022)
9.2.2 Latin America Cell-free Tumor DNA Detection Market Size by Type (2023-2028)
9.2.3 Latin America Cell-free Tumor DNA Detection Market Share by Type (2017-2028)
9.3 Latin America Cell-free Tumor DNA Detection Market Size by Application
9.3.1 Latin America Cell-free Tumor DNA Detection Market Size by Application (2017-2022)
9.3.2 Latin America Cell-free Tumor DNA Detection Market Size by Application (2023-2028)
9.3.3 Latin America Cell-free Tumor DNA Detection Market Share by Application (2017-2028)
9.4 Latin America Cell-free Tumor DNA Detection Market Size by Country
9.4.1 Latin America Cell-free Tumor DNA Detection Market Size by Country (2017-2022)
9.4.2 Latin America Cell-free Tumor DNA Detection Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Cell-free Tumor DNA Detection Market Size (2017-2028)
10.2 Middle East & Africa Cell-free Tumor DNA Detection Market Size by Type
10.2.1 Middle East & Africa Cell-free Tumor DNA Detection Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Cell-free Tumor DNA Detection Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Cell-free Tumor DNA Detection Market Share by Type (2017-2028)
10.3 Middle East & Africa Cell-free Tumor DNA Detection Market Size by Application
10.3.1 Middle East & Africa Cell-free Tumor DNA Detection Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Cell-free Tumor DNA Detection Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Cell-free Tumor DNA Detection Market Share by Application (2017-2028)
10.4 Middle East & Africa Cell-free Tumor DNA Detection Market Size by Country
10.4.1 Middle East & Africa Cell-free Tumor DNA Detection Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Cell-free Tumor DNA Detection Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Biocept Inc.
11.1.1 Biocept Inc. Company Details
11.1.2 Biocept Inc. Business Overview
11.1.3 Biocept Inc. Cell-free Tumor DNA Detection Introduction
11.1.4 Biocept Inc. Revenue in Cell-free Tumor DNA Detection Business (2017-2022)
11.1.5 Biocept Inc. Recent Developments
11.2 Bio-Rad Laboratories Inc.
11.2.1 Bio-Rad Laboratories Inc. Company Details
11.2.2 Bio-Rad Laboratories Inc. Business Overview
11.2.3 Bio-Rad Laboratories Inc. Cell-free Tumor DNA Detection Introduction
11.2.4 Bio-Rad Laboratories Inc. Revenue in Cell-free Tumor DNA Detection Business (2017-2022)
11.2.5 Bio-Rad Laboratories Inc. Recent Developments
11.3 Fluxion Biosciences Inc.
11.3.1 Fluxion Biosciences Inc. Company Details
11.3.2 Fluxion Biosciences Inc. Business Overview
11.3.3 Fluxion Biosciences Inc. Cell-free Tumor DNA Detection Introduction
11.3.4 Fluxion Biosciences Inc. Revenue in Cell-free Tumor DNA Detection Business (2017-2022)
11.3.5 Fluxion Biosciences Inc. Recent Developments
11.4 F. Hoffmann-La Roche AG
11.4.1 F. Hoffmann-La Roche AG Company Details
11.4.2 F. Hoffmann-La Roche AG Business Overview
11.4.3 F. Hoffmann-La Roche AG Cell-free Tumor DNA Detection Introduction
11.4.4 F. Hoffmann-La Roche AG Revenue in Cell-free Tumor DNA Detection Business (2017-2022)
11.4.5 F. Hoffmann-La Roche AG Recent Developments
11.5 Sysmex Europe SE
11.5.1 Sysmex Europe SE Company Details
11.5.2 Sysmex Europe SE Business Overview
11.5.3 Sysmex Europe SE Cell-free Tumor DNA Detection Introduction
11.5.4 Sysmex Europe SE Revenue in Cell-free Tumor DNA Detection Business (2017-2022)
11.5.5 Sysmex Europe SE Recent Developments
11.6 Qiagen
11.6.1 Qiagen Company Details
11.6.2 Qiagen Business Overview
11.6.3 Qiagen Cell-free Tumor DNA Detection Introduction
11.6.4 Qiagen Revenue in Cell-free Tumor DNA Detection Business (2017-2022)
11.6.5 Qiagen Recent Developments
11.7 NeoGenomics Laboratories Inc.
11.7.1 NeoGenomics Laboratories Inc. Company Details
11.7.2 NeoGenomics Laboratories Inc. Business Overview
11.7.3 NeoGenomics Laboratories Inc. Cell-free Tumor DNA Detection Introduction
11.7.4 NeoGenomics Laboratories Inc. Revenue in Cell-free Tumor DNA Detection Business (2017-2022)
11.7.5 NeoGenomics Laboratories Inc. Recent Developments
11.8 Menarini Silicon Biosystems
11.8.1 Menarini Silicon Biosystems Company Details
11.8.2 Menarini Silicon Biosystems Business Overview
11.8.3 Menarini Silicon Biosystems Cell-free Tumor DNA Detection Introduction
11.8.4 Menarini Silicon Biosystems Revenue in Cell-free Tumor DNA Detection Business (2017-2022)
11.8.5 Menarini Silicon Biosystems Recent Developments
11.9 Illumina Inc.
11.9.1 Illumina Inc. Company Details
11.9.2 Illumina Inc. Business Overview
11.9.3 Illumina Inc. Cell-free Tumor DNA Detection Introduction
11.9.4 Illumina Inc. Revenue in Cell-free Tumor DNA Detection Business (2017-2022)
11.9.5 Illumina Inc. Recent Developments
11.10 Guardant Health Inc.
11.10.1 Guardant Health Inc. Company Details
11.10.2 Guardant Health Inc. Business Overview
11.10.3 Guardant Health Inc. Cell-free Tumor DNA Detection Introduction
11.10.4 Guardant Health Inc. Revenue in Cell-free Tumor DNA Detection Business (2017-2022)
11.10.5 Guardant Health Inc. Recent Developments
11.11 Shanghai Biotecan Medical Diagnostics Co.,Ltd.
11.11.1 Shanghai Biotecan Medical Diagnostics Co.,Ltd. Company Details
11.11.2 Shanghai Biotecan Medical Diagnostics Co.,Ltd. Business Overview
11.11.3 Shanghai Biotecan Medical Diagnostics Co.,Ltd. Cell-free Tumor DNA Detection Introduction
11.11.4 Shanghai Biotecan Medical Diagnostics Co.,Ltd. Revenue in Cell-free Tumor DNA Detection Business (2017-2022)
11.11.5 Shanghai Biotecan Medical Diagnostics Co.,Ltd. Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer